A simulation model to evaluate pharmaceutical supply chain costs in hospitals: the case of a Colombian hospital
- 20 Downloads
Healthcare costs is one of the most studied issue in our days because of increasing demand and the aging of population. Final costs of medicines is one of the most important issue in patient treatment and determine its real value is an important task within hospitals. Simulation models and in this case system dynamics allows to build representations of reality considering the interaction of the whole variables that affect the system where first a causal loop diagram allows to represent and identify the interaction between variables for develop a stock flow diagram to determine the final results.
Develop a simulation model that allows decision makers in Hospitals and Governments to identify the variables that affect the final cost of medicines and to determine the legal reimbursement allowed by national agencies.
This paper presents a conceptual modeling framework using a causal loop diagram and a dynamic simulation model in the real case of a hospital in Colombia to explore how different internal charges for medicines affect the behavior of the final unit-dose cost of medicines, considering the complexity of the pharmaceutical system. We developed a simulation model to represent and characterize the pharmaceutical supply chain in a hospital and by using real data we validate the results of the model and conclude about the supply chain of medicines in Colombia using the legal regulations as a main factor of analysis.
Results and conclusions
We found that in some cases the maximum reimbursement value is less than the final cost of medicines within the hospital, which means that hospitals lose money on the administration of medicines to patients. The benefit of this model is that with the result the hospital can determine the real final monetary value of medicines, including the different processes starting from the reception of the medicines, ending with the administration to patients.
KeywordsMedicine costs System dynamics Health care systems Pharmaceutical supply chain Simulation
Compliance with ethical standards
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
- 1.“World Bank,” 2015. [Online]. Available: www.worldbank.org/depweb/spanish/modules/social/pgr/. %5BÚltimo acceso: 1 Agosto 2015.
- 2.“World Health Organization,” 2015. [Online]. Available: www.who.int/mediacentre/news/releases/2014/world-health-statistics-2014/es/. %5BÚltimo acceso: 1 Agosto 2015.
- 3.Z. I. y V. M. V. Mantzana, M. Themistocleou, “Identifying healthcare actors involved in the adoption of information systems,” Eur J Inf Syst, 2007;16: 91–102.Google Scholar
- 5.B. A.-L. Sara Martins, Pedro Amorim, Gonçalo Figueira, “An optimization-simulation approach to the network redesign problem of pharmaceutical wholesalers,” Comput Ind Eng , vol. In press, p. In press, 2017.Google Scholar
- 6.A. Nagurney, M. Yu, A. H. Masoumi, and L. S. Nagurney, “Pharmaceutical Supply Chains,” in Networks Against Time, Springer New York, 2013, pp. 89–116.Google Scholar
- 20.K. Hassmiller Lich, N. D. Osgood, A. Mahamoud, and A. Mahmoud, “Using system dynamics tools to gain insight into intervention options related to the interaction between tobacco and tuberculosis.,” Glob Health Promot, vol. 17, no. 1 Suppl, pp. 7–20, 2010.Google Scholar
- 24.Abdollahiasl A, et al. “A system dynamics model for national drug policy,” DARU. J Pharm Sci. 2014;4(1):1–13.Google Scholar
- 25.Forrester J. Industrial dynamics. Waltham: Pegasus Communications; 1961.Google Scholar
- 26.Ghosh A. Dynamic Systems for Everyone. Plymouth, Massachusetts. In: USA: springer international publishing; 2015.Google Scholar
- 27.J.-R. Borrell, “Drug Price regulation: recent trends and downstream neglected issues,” in Incentives for research, development, and innovation in pharmaceuticals, Madrid: Springer Healthcare Iberica, 2011, pp. 81–96.Google Scholar